Your browser is no longer supported. Please, upgrade your browser.
Adamis Pharmaceuticals Corporation
Index- P/E- EPS (ttm)-0.50 Insider Own1.00% Shs Outstand140.28M Perf Week-17.04%
Market Cap149.00M Forward P/E- EPS next Y-0.19 Insider Trans-10.15% Shs Float92.94M Perf Month-20.00%
Income-34.70M PEG- EPS next Q-0.06 Inst Own4.30% Short Float4.44% Perf Quarter157.77%
Sales18.40M P/S8.10 EPS this Y44.90% Inst Trans-12.66% Short Ratio0.21 Perf Half Y80.70%
Book/sh0.36 P/B3.11 EPS next Y57.80% ROA-78.50% Target Price1.00 Perf Year98.16%
Cash/sh0.09 P/C12.02 EPS next 5Y- ROE-115.90% 52W Range0.27 - 2.34 Perf YTD130.88%
Dividend- P/FCF- EPS past 5Y9.10% ROI-76.90% 52W High-52.14% Beta1.41
Dividend %- Quick Ratio1.20 Sales past 5Y- Gross Margin12.00% 52W Low314.81% ATR0.22
Employees131 Current Ratio1.30 Sales Q/Q-27.10% Oper. Margin- RSI (14)43.87 Volatility12.39% 12.29%
OptionableYes Debt/Eq0.19 EPS Q/Q20.90% Profit Margin- Rel Volume0.19 Prev Close1.12
ShortableYes LT Debt/Eq0.05 Earnings- Payout- Avg Volume19.77M Price1.12
Recom3.00 SMA20-15.36% SMA5010.00% SMA20041.22% Volume3,743,369 Change0.00%
May-13-20Upgrade Maxim Group Hold → Buy $1.50
Feb-27-20Downgrade Dawson James Buy → Neutral
Nov-26-19Downgrade Raymond James Outperform → Mkt Perform
Jul-16-19Downgrade B. Riley FBR Neutral → Sell $1.90 → $1.10
Nov-12-18Downgrade B. Riley FBR Buy → Neutral $7.50 → $2.50
May-11-18Reiterated Maxim Group Buy $5 → $10
Mar-23-18Reiterated B. Riley FBR, Inc. Buy $6.25 → $7.50
Dec-05-17Reiterated Maxim Group Buy $13 → $14
Oct-04-17Resumed B. Riley & Co. Buy $9.50
Jul-21-16Reiterated Maxim Group Buy $17 → $10
Dec-01-15Initiated Maxim Group Buy $16
May-29-15Initiated Mizuho Buy $10
Jan-28-14Initiated CRT Capital Buy $15
Feb-22-21 09:00AM  
Feb-17-21 12:00PM  
Feb-02-21 04:05PM  
Jan-29-21 09:00AM  
Jan-28-21 04:01PM  
Jan-26-21 09:00AM  
Jan-22-21 10:47AM  
Jan-21-21 06:39PM  
Jan-20-21 01:06PM  
Jan-08-21 08:30AM  
Dec-01-20 09:00AM  
Nov-18-20 12:24PM  
Nov-16-20 11:55AM  
Nov-09-20 06:35PM  
Nov-05-20 09:00AM  
Nov-03-20 12:30PM  
Oct-12-20 10:24AM  
Sep-18-20 09:00AM  
Sep-17-20 04:05PM  
Sep-16-20 09:23AM  
Sep-03-20 04:05PM  
Aug-25-20 09:00AM  
Aug-21-20 09:00AM  
Aug-17-20 05:55PM  
Aug-14-20 09:00AM  
Aug-06-20 12:30PM  
Aug-05-20 04:05PM  
Jul-23-20 09:00AM  
Jul-01-20 09:00AM  
Jun-18-20 09:00AM  
Jun-15-20 09:00AM  
May-27-20 09:00AM  
May-25-20 10:37AM  
May-18-20 04:35PM  
May-15-20 09:00AM  
May-12-20 08:06AM  
May-11-20 08:35PM  
Apr-29-20 12:00PM  
Apr-23-20 09:00AM  
Apr-21-20 09:00AM  
Apr-15-20 04:05PM  
Apr-01-20 09:00AM  
Mar-30-20 04:40PM  
Feb-21-20 09:15AM  
Feb-19-20 09:00AM  
Jan-03-20 09:31PM  
Dec-23-19 03:59PM  
Dec-19-19 09:00AM  
Nov-27-19 05:09PM  
Nov-25-19 03:16PM  
Nov-18-19 09:00AM  
Nov-12-19 07:05PM  
Nov-07-19 08:54AM  
Nov-06-19 04:05PM  
Nov-05-19 06:53AM  
Nov-04-19 08:00PM  
Nov-01-19 10:30AM  
Oct-18-19 06:26AM  
Oct-08-19 09:00AM  
Oct-01-19 09:00AM  
Sep-26-19 09:00AM  
Sep-12-19 06:20AM  
Sep-03-19 09:00AM  
Aug-28-19 09:00AM  
Aug-26-19 04:05PM  
Aug-19-19 08:48AM  
Aug-14-19 09:00AM  
Aug-08-19 08:40PM  
Aug-07-19 06:38AM  
Aug-05-19 09:00AM  
Aug-02-19 10:30AM  
Aug-01-19 09:00AM  
Jul-31-19 04:05PM  
Jul-26-19 09:13AM  
Jul-25-19 07:37AM  
Jul-24-19 09:00AM  
Jul-18-19 01:52PM  
Jul-09-19 08:30AM  
Jun-27-19 09:00AM  
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Marguglio David J.SVP and Chief Business OfficerNov 20Sale0.4035,00014,000287,264Nov 24 04:29 PM
Hopkins Robert OChief Financial OfficerNov 20Sale0.4135,00014,182254,810Nov 24 04:26 PM
Moss Ronald B.Chief Medical OfficerNov 18Sale0.418,5323,465231,752Nov 20 04:38 PM
Hopkins Robert OChief Financial OfficerNov 18Sale0.417,2292,936289,810Nov 20 04:34 PM
CARLO DENNIS J PHDPresident & CEONov 18Sale0.4110,6654,331316,405Nov 20 04:33 PM
Daniels Karen K.VP of OperationsNov 18Sale0.415,3332,166149,242Nov 20 04:32 PM
Marguglio David J.SVP and Chief Business OfficerNov 18Sale0.418,5323,465322,264Nov 20 04:31 PM
Hopkins Robert OChief Financial OfficerSep 29Sale0.8020,00016,000274,781Oct 01 06:34 PM
Marguglio David J.SVP and Chief Business OfficerSep 29Sale0.8020,00016,000308,539Oct 01 06:33 PM
Marguglio David J.SVP and Chief Business OfficerAug 18Sale0.878,7497,648328,539Aug 20 05:41 PM
Hopkins Robert OChief Financial OfficerAug 18Sale0.877,4186,484294,781Aug 20 05:38 PM
CARLO DENNIS J PHDPresident & CEOAug 18Sale0.8710,9299,553299,247Aug 20 05:37 PM
Moss Ronald B.Chief Medical OfficerAug 18Sale0.878,7497,648226,373Aug 20 05:36 PM
Daniels Karen K.VP of OperationsAug 18Sale0.875,4804,790140,664Aug 20 05:34 PM
Daniels Karen K.VP of OperationsMay 19Sale0.564,8552,719146,144May 20 04:07 PM
Hopkins Robert OChief Financial OfficerMay 18Sale0.566,5323,659302,199May 20 04:10 PM
Marguglio David J.SVP and Chief Business OfficerMay 18Sale0.567,7344,332337,288May 20 04:09 PM
Moss Ronald B.Chief Medical OfficerMay 18Sale0.567,7364,333235,122May 20 04:08 PM
CARLO DENNIS J PHDPresident & CEOMay 18Sale0.569,9135,552310,176May 20 04:06 PM
Moss Ronald B.Chief Medical OfficerMar 18Sale0.3410,3373,479242,858Mar 19 06:41 PM
Marguglio David J.SVP and Chief Business OfficerMar 18Sale0.3410,3373,479325,022Mar 19 06:40 PM
Hopkins Robert OChief Financial OfficerMar 18Sale0.348,7492,945308,731Mar 19 06:39 PM
Daniels Karen K.VP of OperationsMar 18Sale0.346,4612,175150,999Mar 19 06:36 PM
CARLO DENNIS J PHDPresident & CEOMar 18Sale0.3410,6453,583320,089Mar 19 06:35 PM